Business Context and Reporting Period
This Form 8-K is a current report filed by Oncocyte Corporation (not Insight Molecular Diagnostics Inc.) on December 8, 2021, covering events occurring on December 5, 2021. The filing details the execution of an Addendum to an Exclusive Sublicense Agreement regarding the DetermaRx® technology transfer in the PRC Territory involving Razor Genomics, Inc., Encore Clinical, Inc., and Burning Rock Biotech Limited.
Key Financial Metrics
This filing does not contain comprehensive financial statements, revenue, profit, cash flow, or margin data. The only specific financial figures disclosed relate to the transaction described below:
- Immediate Payment: $2,000,000 payable by Burning Rock to Oncocyte upon completion of the second part of the technology transfer.
- Contingent Payment: $1,000,000 payable within seven days after written confirmation of satisfactory completion of remaining obligations (delivery of user guides, reference materials, and core reagents).
- Deadline: Remaining technology transfer obligations must be completed by April 30, 2022.
Material Changes
The material change reported is the formalization of payment terms for the DetermaRx® technology transfer via an Addendum dated December 5, 2021. This agreement secures a total potential consideration of $3,000,000 from Burning Rock Biotech Limited, contingent upon the successful delivery of specific technical materials and reagents.
Guidance, Outlook, and Risks
The filing includes standard forward-looking statements regarding the completion of technology transfer obligations. Management notes that actual results may differ materially from anticipated results due to risk factors detailed in the company's Annual Report on Form 10-K. The filing explicitly disclaims any obligation to update these forward-looking statements.
Investor Verification Checklist
- Verify the exact terms and conditions of the Addendum (Exhibit 10.1) regarding the $1,000,000 contingent payment.
- Confirm the status of the "remaining technology transfer obligations" and the delivery of user guides and core reagents.
- Review the press release (Exhibit 99.1) for additional context on the commercial relationship with Burning Rock Biotech Limited.
- Note that the registrant is Oncocyte Corporation (Ticker: OCX), not Insight Molecular Diagnostics Inc.